Highlights of FY2015
• Revenue from Quarterly Service Fees – generated by sales of OneTouch Verio blood glucose test strips by LifeScan – up 99% to $12.8 million in FY2015 from $6.4 million in FY2014
• Revenue from supply of test strips for the Siemens Xprecia StrideTM Coagulation Analyzer reach $1.3M in first full year of commercial sales
• Net development expense (after the R&D tax rebate) increased to $10.5 million in FY2015, from $7.2 million in FY2014
• Net loss of $6.6 million in FY2015, an improvement on the net loss of $9.3 million in FY2014
• Positive operating cash flow of $1.8 million, up from negative $(5.4) million in FY2014
• Closing cash balance at 31 December 2015 of $14.4 million
Universal Biosensors (ASX:UBI) today released its full year financial results for FY2015. Total revenue increased 76% to $16.8 million in FY2015, from $9.5 million in FY2014. In FY2015, the key revenue contributor was the Quarterly Service Fees, generated by sales of OneTouch Verio blood glucose test strips by LifeScan, which doubled to $12.8 million in FY2015 (up from $6.4 million in FY2014). In addition, UBI generated $2 million in revenue from milestone payments in FY15, up 12% on FY2014.
For full access, please click here.
